Tildrakizumab, risankizumab, and guselkumab are effective for psoriasis in high-impact areas, though effectiveness varies across affected sites.

While the overall rate of pediatric admissions for dermatologic conditions has declined from 2012 to 2022, significant disparities remain.

The EPA announced plans to add microplastics and leftover medications to its list of priority pollutants in drinking water.

Patients with dermatomyositis in the US experience substantial variability in treatment, high glucocorticoid exposure, and significant healthcare utilization.

The American Heart Association recommended eating plant-based proteins and avoiding dairy fat, contradicting recent federal dietary guidance.

Former US Surgeon General Dr Jerome Adams has joined others in criticizing President Donald Trump’s nominee for the role, Dr Casey Means.

A new vaccine from companies Pfizer and Valneva meant to prevent Lyme disease may be one step closer to approval.

Phase 3 studies showed zasocitinib, a highly selective oral tyrosine kinase 2 inhibitor, provided rapid, durable skin improvement.

The table below is a review of notable updates that occurred in March 2026 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.

Adult acne is affected by sedentary behavior, exercise, and sleep, with depression and anxiety having a significant effect on this relationship.

The US Centers for Disease Control temporarily paused more than 24 types of laboratory tests, reportedly because of a routine review.

Tralokinumab is effective and safe for the treatment of patients with moderate to severe AD through 6 total years of treatment.